Case Reports in Oncology最新文献

{"title":"Cushing's Syndrome due to a Renal Neuroendocrine Tumor: A Case Report.","authors":"Vicka Poudyal, Marianne S Elston, Saleen Nottingham, Michael J Swarbrick, Adam Davies, Veronica Boyle","doi":"10.1159/000545734","DOIUrl":"10.1159/000545734","url":null,"abstract":"<p><strong>Introduction: </strong>Cushing's syndrome (CS) due to ectopic adrenocorticotrophic hormone (ACTH) is rare and usually due to neuroendocrine neoplasia (NEN). Primary renal NEN is exceptionally rare but may be a cause of rapidly progressive CS.</p><p><strong>Case presentation: </strong>A 51-year-old man presented with profound hypokalemia, cellulitis, and new-onset type 2 diabetes and hypertension with 1 month of muscle weakness, labile mood, and insomnia. CS due to ectopic ACTH production was confirmed. Biochemical control was achieved using a \"block-and-replace\" regimen with dual blockade with ketoconazole and metyrapone and hydrocortisone replacement in addition to mineralocorticoid receptor blockade using spironolactone. CT and ultrasound demonstrated a 24 mm right renal lesion with features concerning for renal cell carcinoma. Right laparoscopic nephrectomy was performed. Histology demonstrated a WHO grade one NEN with ACTH staining.</p><p><strong>Conclusion: </strong>In CS, where the source of ectopic ACTH production is unable to be identified, a renal source should be considered. Diagnosis may be difficult as there are no reliable radiological characteristics to distinguish renal NENs from renal cell carcinomas, so a high degree of suspicion is required.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"593-601"},"PeriodicalIF":0.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Immune-Related Adverse Events, Including Myasthenia Gravis, Myositis, and Myocarditis, during Avelumab and Axitinib Combination Therapy.","authors":"Jurii Karibe, Ryohei Horiguchi, Yohei Hanajima, Akihito Hashizume, Daiji Takamoto, Takashi Kawahara, Kimito Osaka, Jun-Ichi Teranishi, Naohisa Ueda, Hiroji Uemura","doi":"10.1159/000545733","DOIUrl":"https://doi.org/10.1159/000545733","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors are the mainstay of treatment for unresectable or metastatic renal cell carcinoma (RCC). However, they can cause immune-related adverse events (irAEs), and the management of these irAEs is critical. The combination of myasthenia gravis, myositis, and myocarditis, which are irAEs, is rare, and it has not been reported to occur with avelumab. This report aimed to present a rare case of RCC metastasis that developed irAEs during avelumab and axitinib combination therapy.</p><p><strong>Case presentation: </strong>A 76-year-old woman who underwent radical nephrectomy for clear cell RCC (pT1bN0M0 Grade 3 INFb) at the age of 67 years presented to our hospital after her family doctor noted a pancreatic tumor. She was diagnosed with pancreatic metastasis of RCC based on histopathological examination, and avelumab and axitinib combination therapy was initiated. She developed irAEs, including myasthenia gravis, myositis, and myocarditis, which were treated with steroid pulse therapy. The patient recovered after treatment and was discharged without sequelae.</p><p><strong>Conclusion: </strong>Myasthenia gravis, myositis, and myocarditis can occur during avelumab and axitinib combination therapy for RCC. Prompt diagnosis, treatment, and collaboration with other departments are extremely important for managing irAEs.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"563-569"},"PeriodicalIF":0.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review.","authors":"Taiki Ishida, Ken Morita, Yosuke Masamoto, Hideaki Mizuno, Kazuki Taoka, Hiroyuki Abe, Motoki Odawara, Yosuke Hirakawa, Masaomi Nangaku, Mineo Kurokawa","doi":"10.1159/000545498","DOIUrl":"https://doi.org/10.1159/000545498","url":null,"abstract":"<p><strong>Introduction: </strong>Fibrillary glomerulonephritis (FGN) is a rare form of immune complex-mediated primary glomerular disease frequently coexisting with malignancies or autoimmune diseases. The kidney prognosis is extremely poor, with approximately 50% of patients progressing to end-stage kidney disease within 2-4 years after diagnosis. However, no established treatment currently exists.</p><p><strong>Case presentation: </strong>Here we describe a rare case of FGN diagnosed in a patient progressing from monoclonal gammopathy to multiple myeloma. The histopathological findings of the kidney biopsy were consistent with classical FGN and revealed no evidence of myeloma cast nephropathy. Albumin-dominant, Bence Jones protein-negative proteinuria further supported this diagnosis. The patient was successfully treated with anti-myeloma chemotherapies including autologous stem cell transplant, resulting in significant improvement in kidney function.</p><p><strong>Conclusion: </strong>Based on our experience, secondary FGN associated with plasma cell neoplasms may represent a rare entity that responds favorably to anti-myeloma therapies. Initial investigations to rule out coexistent plasma cell neoplasms are crucial for the optimal management of FGN patients.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"554-562"},"PeriodicalIF":0.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excellent Response to Trastuzumab Deruxtecan of a Large Medullary Metastasis from Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Case Report.","authors":"Aoi Kuroda, Mao Uematsu, Mai Shimura, Akira Hirota, Misao Fukuda, Nobuyuki Takahashi, Hiromichi Nakajima, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Yoichi Naito, Toru Mukohara","doi":"10.1159/000545577","DOIUrl":"https://doi.org/10.1159/000545577","url":null,"abstract":"<p><strong>Introduction: </strong>Brain metastasis is a serious complication in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Brainstem metastases are particularly challenging to treat because of the high risks associated with surgery and stereotactic radiosurgery (SRS).</p><p><strong>Case presentation: </strong>We present a case of a 56-year-old woman with HER2-positive breast cancer who developed multiple brain metastases, including a large medullary lesion, 9 months after surgery confirming a pathological complete response to standard trastuzumab plus pertuzumab-based neoadjuvant chemotherapy, without extracranial lesions. Surgery was deemed infeasible because the lesion's location and size posed high risks of toxicity from SRS. Promising intracranial responses to trastuzumab deruxtecan (T-DXd) have been reported; therefore, T-DXd was chosen. Remarkable symptomatic improvements were observed within days after initiating T-DXd. Imaging confirmed radiographic responses and metabolic response indicated by the absence of uptake of ¹¹C-methionine on positron emission tomography-computed tomography. No evidence of relapse has been observed after the 14 months since the initiation of T-DXd.</p><p><strong>Conclusion: </strong>This case indicates the efficacy of T-DXd in treating large medullary metastases, achieving rapid and sustained responses even in high-risk situations where conventional therapies may not be suitable. Furthermore, the fact that the brain metastases occurred after pathological complete response without extracranial lesions may indicate the superiority of T-DXd over conventional anti-HER2 antibodies for brain metastasis. This case underscores the potential of T-DXd as a viable treatment option for brain metastases. Further studies are required to establish its safety and efficacy in similar high-risk scenarios.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"523-530"},"PeriodicalIF":0.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Light-Chain (AL) Amyloidosis as a Rare Cause of Upper Gastrointestinal Bleeding: A Case Report and Systematic Literature Review.","authors":"Christoph Müller, Arne Warth","doi":"10.1159/000545586","DOIUrl":"https://doi.org/10.1159/000545586","url":null,"abstract":"<p><strong>Introduction: </strong>Amyloidosis is a rare disease characterized by the deposition of misfolded proteins in different organs leading to tissue damage and organ failure. The immunoglobulin light chain produced by a monoclonal B-cell is one of more than 30 proteins identified to cause amyloidosis. Most commonly affecting the heart and kidneys, AL (amyloid, light chain) -amyloidosis can occur in any organ except for the central nervous system and carries a high morbidity and mortality. Gastrointestinal involvement is observed rather rarely and can present with intestinal obstruction, weight loss, hematochezia, malabsorption, or hematemesis. In this case report and systematic review, we present a 76-year-old male patient with new onset recurrent hematemesis and melena due to duodenal AL-amyloidosis and give a summary on the reported cases of upper gastrointestinal bleeding caused by the disease.</p><p><strong>Case report: </strong>The report of this case was guided by the CARE guidelines and served as an example to allow for a discussion of the specific aspects of upper gastrointestinal bleeding in AL-amyloidosis. A comprehensive literature search was conducted using the databases PubMed, Embase and Google Scholar. After applying the eligibility criteria, a total count of 26 were included into the systematic review which was reported according to the PRISMA checklist. The reported case showed recurrent hematemesis as the initial symptom of AL-amyloidosis due to B-cell dyscrasia and appeared to be characteristic of patients presenting with primary gastrointestinal involvement. Summarizing the biometric and clinical details of the individuals included into the systematic review, we observed a mean age of 66 years, a slight female predominance and a preferred clinical manifestation in the stomach and duodenum with localized disease in 38% of all cases.</p><p><strong>Conclusion: </strong>Although being a rare cause of upper gastrointestinal bleeding, AL-amyloidosis should be considered in patients with endoscopic findings of systemic disease and a clinical condition of suspected or known B-cell dyscrasia. An early diagnosis is crucial for patients with AL-amyloidosis as the disease often shows a rapid progression and treatment with combined personalized-/chemotherapy is usually well tolerated and highly efficient.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"539-553"},"PeriodicalIF":0.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epithelioid Malignant Peripheral Nerve Sheath Tumor of the Breast with Breast Cancer in the Contralateral Breast: A Case Report.","authors":"Reona Fukada, Ayumi Murakami, Tomoko Wada, Hitoshi Inari, Tatsuya Yoshida","doi":"10.1159/000545496","DOIUrl":"https://doi.org/10.1159/000545496","url":null,"abstract":"<p><strong>Introduction: </strong>Malignant peripheral nerve sheath tumors (MPNSTs) are common in the peripheral nerves of the head, neck, and limbs, with few reports of their occurrence in the breasts, and the epithelioid type is rare. Here, we aimed to report a case of an epithelioid MPNST of the breast.</p><p><strong>Case presentation: </strong>A 76-year-old woman presented with bilateral breast masses. Pathological findings showed a 60-mm invasive ductal carcinoma (T3N0M0 stage IIB) on the right breast and an epithelioid MPNST on the left breast. After surgical resection, the patient was treated with endocrine therapy alone for right breast cancer, and no recurrence was observed 4 years after surgery.</p><p><strong>Conclusion: </strong>Reports of MPNSTs in the breasts are rare. The pathological analysis showed atypia of spindle cells, positive staining for vimentin, S100, SOX10, and epithelial-like cells, and positive staining for cytokeratin AE1/AE3. H3K27me3 is reportedly absent in typical MPNSTs; however, it is expressed in epithelioid types. It sometimes occurs in patients with a germline mutation in <i>SMARCB1/INI1</i>, where INI1 is absent in tumor cells. In this case, the tumor cells expressed H3K27me3 and also maintained INI1.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"531-538"},"PeriodicalIF":0.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precise Localization of the Subsolid Lesion by Colour Marking under CT-Guided Control before Video-Assisted Surgery Resection: A Case Report.","authors":"Vladimír Červeňák, Zdeněk Chovanec, Jan Resler, Tomáš Hanslík, Alena Berková, Ondřej Bílek, Klára Novosádová, Viktor Weiss, Jiří Vaníček","doi":"10.1159/000545435","DOIUrl":"https://doi.org/10.1159/000545435","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer is one of the leading causes of death worldwide. Lung lesions, often discovered incidentally on chest CT, pose a diagnostic challenge due to their diverse etiology, including both benign and malignant nature. A key step in the assessment of these lesions is the evaluation of their morphological features in the CT image, size, and behavior over time. Nodules are divided into solid and subsolid according to their density. When surgical resection is necessary, solid lesions are palpable peroperatively, whereas subsolid lesions may be unidentifiable by palpation, and their precise localization is difficult. To spare patients from extensive surgery such as thoracotomy, it is advantageous to use one of the methods of preoperative marking of these lesions. Best practices include marking with mixtures containing patent blue and contrast agents, applied under CT guidance. This method allows accurate visualization of the localization of the lesion, which facilitates their resection by minimally invasive video-assisted surgery (VATS).</p><p><strong>Case presentation: </strong>A 51-year-old female patient was found to have a subsolid lesion in the right lung during a routine follow-up CT scan of the lung for a history of malignant melanoma. The lesion was followed for 4 years and showed slow size progression and change from a pure ground glass nodule to a subsolid nodule. Due to the persistence of the nodule, change in morphology, and size progression, the patient was indicated for surgical resection. Using preoperative labeling with a mixture of blue dye and contrast agent, the nodule was successfully located and sublobary VATS resected.</p><p><strong>Conclusion: </strong>The color marking allowed accurate identification of the subpleurally located lesion, which would otherwise have been unvisualized and intangible, thus minimizing the need for more extensive surgery. This case highlights the key role of color marking in increasing resection success and surgical safety, particularly in small and subsolid nodules.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"508-514"},"PeriodicalIF":0.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maxillary Ewing Sarcoma in a Teenager: A Case Report.","authors":"Ahmad Al-Bitar, Mahdi Sandouk","doi":"10.1159/000545490","DOIUrl":"https://doi.org/10.1159/000545490","url":null,"abstract":"<p><strong>Introduction: </strong>Ewing sarcoma (ES) is an aggressive primary bone cancer, primarily affecting children and adolescents, accounting for 5% of cancers in this demographic. ES most commonly affects males during adolescence. It primarily targets flat and long bones such as the pelvis, femur, tibia, and fibula, and less frequently, the mandible and maxilla.</p><p><strong>Case presentation: </strong>This case report details a 14-year-old Arab female with maxillary ES, highlighting diagnostic and therapeutic challenges. The patient presented with jaw pain and swelling, initially evaluated via radiography and biopsy, revealing classic histopathological features (small round blue cells, Homer-Wright rosettes) and immunohistochemical markers (CD99, NKX2.2, FLI1 positivity). Imaging identified a localized maxillary mass (T4a N0 M0). Multimodal therapy included neoadjuvant chemotherapy (VDC/IE regimen), en bloc resection, adjuvant chemotherapy, and dental rehabilitation.</p><p><strong>Conclusion: </strong>Craniofacial ES often mimics benign odontogenic lesions, delaying diagnosis; this case achieved timely intervention within 7 months. Unlike axial ES, jaw tumors require balancing oncologic control with functional preservation, emphasizing conservative surgery and multidisciplinary rehabilitation. The patient's outcome aligns with studies showing superior survival for craniofacial ES (82% 5-year survival) compared to pelvic sites.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"515-522"},"PeriodicalIF":0.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report.","authors":"Shinichi Maruyama, Masaru Kato, Masaru Ishida, Tatsuru Hiraga, Hiroshi Kanno","doi":"10.1159/000545249","DOIUrl":"https://doi.org/10.1159/000545249","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment strategies for metastatic renal cell carcinoma (mRCC) have advanced, and its prognosis has improved. However, the progression-free survival of patients with mRCC who have received prior treatment is approximately 8 months, and long-term responses are rare. We applied therapeutic drug monitoring to a case of mRCC in which a long-term response of more than 3 years was achieved after the administration of cabozantinib as third-line treatment. Here, we report the changes in the blood concentration of cabozantinib.</p><p><strong>Case presentation: </strong>The patient was a 67-year-old man who had received sunitinib as the first-line treatment and nivolumab as the second-line treatment for stage IV mRCC. However, the disease progressed, and cabozantinib (40 mg/day) was initiated. Three months after the initiation of cabozantinib, partial tumor shrinkage was achieved. In the sixth month, the dose was reduced to 20 mg/day because of severe palmar-plantar erythrodysesthesia syndrome and anorexia; however, further tumor shrinkage was achieved. Fifteen months after starting cabozantinib, the trough concentration of cabozantinib was 960 ng/mL. Thereafter, cabozantinib concentration was measured almost every month and was found to fluctuate between 583 and 1,938 ng/mL; tumor shrinkage was maintained even at 39 months.</p><p><strong>Conclusion: </strong>Cabozantinib provided long-term benefits for more than 3 years. We emphasize that the measurement of cabozantinib concentration in the blood may play a supporting role as an indicator of long-term response.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"500-507"},"PeriodicalIF":0.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report.","authors":"Zhi-Ping Liu, Si-Han Liu, He Zhao, Fang-Ying Ruan, Da-Xin Zhang, Bai Xu","doi":"10.1159/000545068","DOIUrl":"https://doi.org/10.1159/000545068","url":null,"abstract":"<p><strong>Introduction: </strong>Limited treatment options are available for residual locally advanced cervical cancer after concurrent radio-chemotherapy. Pembrolizumab has been approved by the US Food and Drug Administration to treat patients with persistent, recurrent, and metastatic cervical cancer. However, it is expensive and not covered by medical insurance in China.</p><p><strong>Case description: </strong>A patient presented with stage IIIC1 cervical cancer characterized by PTEN, PIK3CA, MTOR, and ARID1A mutations, accompanied by low programmed cell death-ligand 1 expression (tumor cell proportion score 1% and combined positive score 1). The patient exhibited a residual cervical lesion after concurrent radio-chemotherapy but eventually achieved a pathologically complete response through a combination of the programmed cell death-1 (PD-1) inhibitor camrelizumab with the antiangiogenic drug apatinib (two medicines produced by Chinese Jiangsu Hengrui Pharmaceutical Co.). Surgical intervention confirmed the lack of residual tumor cells in the cervix. Regular follow-up confirmed that disease-free survival time was 41 months and overall survival time was 51 months. Adverse events, including cutaneous capillary endothelial proliferation, hepatic insufficiency, hemorrhoidal hemorrhage, and neutropenia, were manageable during treatment with camrelizumab and apatinib.</p><p><strong>Conclusion: </strong>Our findings suggest that the combination of camrelizumab and apatinib could offer a valuable therapeutic option for residual advanced cervical cancer patients after concurrent radio-chemotherapy. Camrelizumab is affordable, at just 10% of the price of pembrolizumab, although it is similarly not covered by medical insurance for cervical cancer in China. The PTEN, PIK3CA, MTOR, and ARID1A gene mutations hold the potential to serve as predictive biomarkers for cervical cancer patients treated by PD-1 inhibitors.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"480-492"},"PeriodicalIF":0.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}